On March 11, 2022, the FDA approved olaparib for the adjuvant treatment of patients with BRCA mutations presenting HER2-negative high-risk early breast cancer who completed definitive local treatment and neoadjuvant or adjuvant chemotherapy. Here, ERBB2 is linked to breast carcinoma.